HomeCompareESALF vs SBUX

ESALF vs SBUX: Dividend Comparison 2026

ESALF yields 3.60% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $132.1K in total portfolio value
10 years
ESALF
ESALF
● Live price
3.60%
Share price
$30.00
Annual div
$1.08
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$474.23
Full ESALF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — ESALF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALF
Annual income on $10K today (after 15% tax)
$306.00/yr
After 10yr DRIP, annual income (after tax)
$403.10/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $55,561.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALF + SBUX for your $10,000?

ESALF: 50%SBUX: 50%
100% SBUX50/50100% ESALF
Portfolio after 10yr
$91.4K
Annual income
$33,157.17/yr
Blended yield
36.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

ESALF
No analyst data
Altman Z
2.9
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALF buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALFSBUX
Forward yield3.60%2.75%
Annual dividend / share$1.08$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%48.3%
Portfolio after 10y$25.4K$157.5K
Annual income after 10y$474.23$65,840.13
Total dividends collected$4.2K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: ESALF vs SBUX ($10,000, DRIP)

YearESALF PortfolioESALF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,061$361.44$11,107$407.21$46.00SBUX
2$12,211$375.14$12,512$626.87$301.00SBUX
3$13,454$388.58$14,366$978.69$912.00SBUX
4$14,798$401.74$16,929$1,557.50$2.1KSBUX
5$16,248$414.60$20,658$2,543.80$4.4KSBUX
6$17,813$427.16$26,406$4,302.22$8.6KSBUX
7$19,499$439.41$35,877$7,622.00$16.4KSBUX
8$21,315$451.34$52,741$14,352.64$31.4KSBUX
9$23,270$462.94$85,676$29,243.03$62.4KSBUX
10$25,373$474.23$157,513$65,840.13$132.1KSBUX

ESALF vs SBUX: Complete Analysis 2026

ESALFStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this ESALF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALF vs SCHDESALF vs JEPIESALF vs OESALF vs KOESALF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.